Metsera (NASDAQ:MTSR) Hits New 1-Year Low – Here’s What Happened

Metsera, Inc. (NASDAQ:MTSR)’s share price hit a new 52-week low on Tuesday . The company traded as low as $15.34 and last traded at $16.45, with a volume of 1606066 shares changing hands. The stock had previously closed at $16.80.

Wall Street Analysts Forecast Growth

MTSR has been the topic of several research reports. Guggenheim initiated coverage on shares of Metsera in a report on Tuesday, February 25th. They set a “buy” rating and a $56.00 price objective on the stock. Cantor Fitzgerald initiated coverage on shares of Metsera in a report on Tuesday, February 25th. They set an “overweight” rating on the stock. Evercore ISI started coverage on shares of Metsera in a report on Tuesday, February 25th. They set an “outperform” rating on the stock. Finally, Bank of America started coverage on shares of Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price target on the stock.

Metsera Stock Performance

The company has a 50-day simple moving average of $26.28.

Metsera (NASDAQ:MTSR) last released its earnings results on Wednesday, March 26th. The company reported ($3.52) EPS for the quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.